Workflow
NextSeq550AR测序仪
icon
Search documents
安诺优达再度递表港交所 报告期内累计亏损超4.6亿元
Zhi Tong Cai Jing· 2025-10-01 02:12
据港交所9月30日披露,安诺优达基因科技(北京)股份有限公司(简称:安诺优达)递表港交所主板,建银国际、 国泰君安国际为其联席保荐人。该公司曾于3月25日向港交所递交上市申请。 招股书显示,安诺优达是一家专注于以分子诊断为基础的IVD医疗器械及多组学生命科学研究服务的公司,亦 专精于基于NGS的产前检测IVD产品。公司临床测序解决方案包括自产基于基因测序的IVD检测试剂盒、基因 测序仪及生物信息学分析软件,以及配套技术支持及实验室设计服务。 公司的客户主要包括产前诊断认证的医院及独立医学实验室(ICL)。该等机构客户购买公司的IVD产品,公司根 据该等客户购买IVD产品的数目及类型收取费用。 公司的NIPT试剂盒(旨在检测三种最常见的染色体疾病(21、18及13三体综合症))于2017年获得三类医疗器械证 书,并在产前检测市场建立市场地位。根据灼识咨询的资料,按样本检测量计量,于2024年,公司在中国NIPT 市场位列第二,于2022年、2023年及2024年的市场份额持续增长,分别为11.6%、12.1%及15.5%。此外,按收 入计,公司于中国NIPT市场排名第三,市场份额为14.6%。 在临床测序解决方 ...
比亚迪联创夏佐全,IVD医疗新贵安诺优达赴港IPO能否成功?
Sou Hu Cai Jing· 2025-03-27 12:17
Core Viewpoint - Anuo Youda has submitted its listing application to the Hong Kong Stock Exchange, marking its journey towards going public, backed by influential figure Xia Zuoquan, co-founder of BYD and angel investor in UBTECH [1] Company Overview - Anuo Youda, founded in 2012 by Xia Zuoquan, specializes in IVD medical devices and multi-omics life science research services, becoming a pioneer in NGS-based prenatal testing IVD products [1][3] - The company has developed a comprehensive IVD product portfolio, including approved testing kits, sequencers, and compatible bioinformatics analysis software [3] Market Position - According to data from Zhaoshang Consulting, Anuo Youda ranks third in the Chinese NIPT market by sample testing volume, with a market share of 12.1% [2][3] - The company has significantly increased its sales of IVD products to 86 certified hospitals across 26 provinces, reflecting a growing demand for its offerings [3] Financial Performance - Anuo Youda's revenue projections for 2022 to 2024 are 435 million, 475 million, and 518 million yuan, indicating an upward trend in market demand [3] - Despite rapid business growth, the company is currently operating at a loss, with projected losses of 66.81 million, 240 million, and 126 million yuan for the same period [4] Shareholder Structure - The company boasts a strong shareholder structure, including notable investors such as China Life, Northern Light Venture Capital, Guotai Junan, Ping An Group, and Sequoia Capital, providing financial support and strategic guidance [4] - Xia Zuoquan controls 54.25% of the voting rights through direct and indirect holdings, although daily management is led by CEO Li Zhimin, who has over 30 years of experience in the pharmaceutical and medical industry [4][5] Leadership - Xia Zuoquan is recognized for his visionary leadership and business acumen, which are key to Anuo Youda's success, alongside CEO Li Zhimin's extensive industry insights [5]
比亚迪联合创始人,即将收获又一家IPO
Zheng Quan Shi Bao· 2025-03-27 09:43
最新数据显示,夏佐全目前个人仍位列比亚迪前十大股东之列,持股比例为2.84%,持股数达8263万股,总市值超过300亿元。 | ▶十大股东 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 实际控制人:王传福(直接持股比例:17.65%) | | | | | | | | | I | 2024-12-31 2024-09-30 | 2024-06-30 | 2024-04-12 | 2024-03-31 | 2024-03-05 | 2023-12-31 | 2023-09-30 | 2023-06-3 >> | | 名次 | 股东名称 | | | 股份类型 | 持股数(股) | 占总股本持 股比例 | 增减(股) | 变动比例 | | 1 | HKSCC NOWINEES LINED | | | 流通用股 | 1,097, 459, 799 | 37.72% | 6,100 | 0.00% | | 2 | 干传福 | | | 流通A股,限售流通A股 | 513, 623, 850 | 17. 65% | ...